Literature DB >> 11348271

MCF-10AT: A Model for Human Breast Cancer Development.

Gloria H. Heppner1, Sandra R. Wolman.   

Abstract

A number of lesions, collectively termed Proliferative Breast Disease (PBD), have been associated with high risk of developing breast cancer. Understanding of the natural history of PBD and its relationship to breast cancer progression has been hampered by the lack of an experimental model. MCF-10AT cells are of human, breast epithelial cell origin. They grow as xenografts in immune-incompetent mice where they produce normal-appearing ducts, atypical hyperplasia, carcinoma-in-situ, and invasive carcinoma. Estrogen supplementation of the mice accelerates development of cancer. The MCF-10AT model of PBD offers a new approach to the study of early breast cancer progression and its prevention.

Entities:  

Year:  1999        PMID: 11348271     DOI: 10.1046/j.1524-4741.1999.00136.x

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


  20 in total

1.  Altered glucose metabolism in Harvey-ras transformed MCF10A cells.

Authors:  Wei Zheng; Fariba Tayyari; G A Nagana Gowda; Daniel Raftery; Eric S McLamore; D Marshall Porterfield; Shawn S Donkin; Brian Bequette; Dorothy Teegarden
Journal:  Mol Carcinog       Date:  2013-09-02       Impact factor: 4.784

2.  The ER structural protein Rtn4A stabilizes and enhances signaling through the receptor tyrosine kinase ErbB3.

Authors:  Jason Hatakeyama; Jessica H Wald; Hanine Rafidi; Antonio Cuevas; Colleen Sweeney; Kermit L Carraway
Journal:  Sci Signal       Date:  2016-06-28       Impact factor: 8.192

3.  Hedgehog signaling and response to cyclopamine differ in epithelial and stromal cells in benign breast and breast cancer.

Authors:  Shibani Mukherjee; Natalya Frolova; Andrea Sadlonova; Zdenek Novak; Adam Steg; Grier P Page; Danny R Welch; Susan M Lobo-Ruppert; J Michael Ruppert; Martin R Johnson; Andra R Frost
Journal:  Cancer Biol Ther       Date:  2006-06-18       Impact factor: 4.742

4.  The nucleoporin ELYS regulates nuclear size by controlling NPC number and nuclear import capacity.

Authors:  Predrag Jevtić; Andria C Schibler; Chase C Wesley; Gianluca Pegoraro; Tom Misteli; Daniel L Levy
Journal:  EMBO Rep       Date:  2019-05-13       Impact factor: 8.807

5.  Metastatic State of Cancer Cells May Be Indicated by Adhesion Strength.

Authors:  Alexander Fuhrmann; Afsheen Banisadr; Pranjali Beri; Thea D Tlsty; Adam J Engler
Journal:  Biophys J       Date:  2017-02-28       Impact factor: 4.033

6.  Human breast fibroblasts inhibit growth of the MCF10AT xenograft model of proliferative breast disease.

Authors:  Andrea Sadlonova; Shibani Mukherjee; Damon B Bowe; Sandra R Gault; Nicole A Dumas; Brian A Van Tine; Natalya Frolova; Grier P Page; Danny R Welch; Lea Novak; Andra R Frost
Journal:  Am J Pathol       Date:  2007-03       Impact factor: 4.307

7.  A novel aptamer developed for breast cancer cell internalization.

Authors:  Kejing Zhang; Kwame Sefah; Lili Tang; Zilong Zhao; Guizhi Zhu; Mao Ye; Weijia Sun; Steve Goodison; Weihong Tan
Journal:  ChemMedChem       Date:  2011-12-14       Impact factor: 3.466

8.  Genistein depletes telomerase activity through cross-talk between genetic and epigenetic mechanisms.

Authors:  Yuanyuan Li; Liang Liu; Lucy G Andrews; Trygve O Tollefsbol
Journal:  Int J Cancer       Date:  2009-07-15       Impact factor: 7.396

9.  Cell Adhesiveness Serves as a Biophysical Marker for Metastatic Potential.

Authors:  Pranjali Beri; Anna Popravko; Benjamin Yeoman; Aditya Kumar; Kevin Chen; Enio Hodzic; Alyssa Chiang; Afsheen Banisadr; Jesse K Placone; Hannah Carter; Stephanie I Fraley; Parag Katira; Adam J Engler
Journal:  Cancer Res       Date:  2019-12-19       Impact factor: 12.701

10.  Identification of PADI2 as a potential breast cancer biomarker and therapeutic target.

Authors:  John L McElwee; Sunish Mohanan; Obi L Griffith; Heike C Breuer; Lynne J Anguish; Brian D Cherrington; Ashley M Palmer; Louise R Howe; Venkataraman Subramanian; Corey P Causey; Paul R Thompson; Joe W Gray; Scott A Coonrod
Journal:  BMC Cancer       Date:  2012-10-30       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.